IP Library Granted Patent US 8,343,952
Granted Patent B2
US 8,343,952 · App. 12/860,073 · Granted Jan 1, 2013

Prolyl hydroxylase inhibitors and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,343,952
App. No.
12/860,073
Granted
Jan 1, 2013
Kind
B2
Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Claims (175)

1. A compound having the formula:

wherein R 2 is chosen from:

i) —OR 6 ; or

ii) —NR 7a R 7b ;

R 6 is hydrogen, methyl, or ethyl;

R 7a and R 7b are each independently:

i) hydrogen; or

ii) methyl;

R 3 is hydrogen or methyl;

R 8a and R 8b are each independently hydrogen, methyl, or ethyl;

R 10 represents from 1 to 5 substitutions for hydrogen, said substitutions independently chosen from:

i) fluoro;

ii) chloro;

iii) trifluoromethyl;

iv) methyl; or

v) two adjacent R 10 units can be taken together to form a 6-member ring having one or two oxygen atoms, provided no two oxygen atoms are adjacent to one another in the ring; and

pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 , having the formula:

3. The compound according to claim 2 , wherein R 2 is —OH.

4. The compound according to claim 2 , wherein R 2 is —OCH 3 or —OCH 2 CH 3 .

5. The compound according to claim 2 , wherein R 2 is chosen from —NH 2 , —NHCH 3 , or —N(CH 3 ) 2 .

6. The compound according to claim 2 , wherein R 8a and R 8b are both hydrogen.

7. The compound according to claim 1 , having the formula:

8. The compound according to claim 7 , wherein R 2 is —OH.

9. The compound according to claim 7 , wherein R 2 is —OCH 3 or —OCH 2 CH 3 .

10. The compound according to claim 7 , wherein R 2 is chosen from —NH 2 , —NHCH 3 , or —N(CH 3 ) 2 .

11. The compound according to claim 7 , wherein R 8a and R 8b are both hydrogen.

12. The compound according to claim 1 , having the formula:

13. The compound according to claim 12 , wherein R 2 is —OH.

14. The compound according to claim 12 , wherein R 2 is —OCH 3 or —OCH 2 CH 3 .

15. The compound according to claim 12 , wherein R 2 is chosen from —NH 2 , —NHCH 3 , or —N(CH 3 ) 2 .

16. The compound according to claim 12 , wherein R 8a and R 8b are both hydrogen.

17. The compound according to claim 1 , having the formula:

18. The compound according to claim 17 , wherein R 2 is —OH.

19. The compound according to claim 17 , wherein R 2 is —OCH 3 or —OCH 2 CH 3 .

20. The compound according to claim 17 , wherein R 2 is chosen from —NH 2 , —NHCH 3 , or —N(CH 3 ) 2 .

21. The compound according to claim 17 , wherein R 8a and R 8b are both hydrogen.

22. The compound according to claim 1 , having the formula:

23. The compound according to claim 22 , wherein R 2 is —OH.

24. The compound according to claim 22 , wherein R 2 is —OCH 3 or —OCH 2 CH 3 .

25. The compound according to claim 22 , wherein R 2 is chosen from —NH 2 , —NHCH 3 , or —N(CH 3 ) 2 .

26. The compound according to claim 22 , wherein R 8a and R 8b are both hydrogen.

27. A compound chosen from:

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester;

5-(3-Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid methyl ester;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid ethyl ester;

5-(3-Chlorophenyl)-N-(1-methyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(1-methyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(1-methyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid methyl ester;

{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid ethyl ester;

5-(3-Chlorophenyl)-N-(1,1-dimethyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(1,1-dimethyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chlorophenyl)-N-(1,1-dimethyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester;

5-(4-Fluorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Fluorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(4-Fluorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid methyl ester;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid ethyl ester;

5-(4-Fluorophenyl)-N-(1-methyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(4-Fluorophenyl)-N-(1-methyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(4-Fluorophenyl)-N-(1-methyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid methyl ester;

{[5-(4-Fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid ethyl ester;

5-(4-Fluorophenyl)-N-(1,1-dimethyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(4-Fluorophenyl)-N-(1,1-dimethyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(4-Fluorophenyl)-N-(1,1-dimethyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester;

5-(3-Trifluoromethylphenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Trifluoromethylphenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Trifluoromethylphenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid methyl ester;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid ethyl ester;

5-(3-Trifluoromethylphenyl)-N-(1-methyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Trifluoromethylphenyl)-N-(1-methyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Trifluoromethylphenyl)-N-(1-methyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid methyl ester;

{[5-(3-Trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid ethyl ester;

5-(3-Trifluoromethylphenyl)-N-(1,1-dimethyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Trifluoromethylphenyl)-N-(1,1-dimethyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Trifluoromethylphenyl)-N-(1,1-dimethyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester;

5-(3-Chloro-6-methyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chloro-6-methyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chloro-6-methyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid methyl ester;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid ethyl ester;

5-(3-Chloro-6-methyl)-N-(1-methyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chloro-6-methyl)-N-(1-methyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chloro-6-methyl)-N-(1-methyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid methyl ester;

{[5-(3-Chloro-6-methyl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid ethyl ester;

5-(3-Chloro-6-methyl)-N-(1,1-dimethyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(3-Chloro-6-methyl)-N-(1,1-dimethyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; and

5-(3-Chloro-6-methyl)-N-(1,1-dimethyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid;

{[5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;

{[5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid;

{[5-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid methyl ester;

{[5-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}-2-methylacetic acid ethyl ester;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(1-methyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(1-methyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(1-methyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

{[5-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid;

{[5-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid methyl ester;

{[5-(2,3-dihydrobenzo [1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}-2,2-dimethylacetic acid ethyl ester;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(1,1-dimethyl-2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(1,1-dimethyl-2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; and

5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N-(1,1-dimethyl-2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;

or a pharmaceutically acceptable salt thereof

28. A composition for treating anemia, comprising:

A) One or more compounds having the formula:

wherein R 2 is chosen from:

i) —OR 6 ; or

ii) —NR 7a R 7b ;

R 6 is hydrogen, methyl, or ethyl;

R 7a and R 7b are each independently:

i) hydrogen; or

ii) methyl;

R 3 is hydrogen or methyl;

R 8a and R 8b are each independently hydrogen, methyl, or ethyl;

R 10 represents from 1 to 5 substitutions for hydrogen, said substitutions independently chosen from:

i) fluoro;

ii) chloro;

iii) trifluoromethyl;

iv) methyl; or

v) two adjacent R 10 units can be taken together to form a 6-member ring having one or two oxygen atoms, provided no two oxygen atoms are adjacent to one another in the ring; and

pharmaceutically acceptable salts thereof; and

B) one or more pharmaceutically acceptable excipients.

29. The composition according to claim 28 , wherein the compound is chosen from {[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, {[5-(4-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, {[5-(3-trifluoromethylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, and {[5-(3-chloro-6-methylphenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.

30. A composition for treating wounds, comprising:

A) One or more compounds having the formula:

wherein R 2 is chosen from:

i) —OR 6 ; or

ii) —NR 7a R 7b ;

R 6 is hydrogen, methyl, or ethyl;

R 7a and R 7b are each independently:

i) hydrogen; or

ii) methyl;

R 3 is hydrogen or methyl;

R 8a and R 8b are each independently hydrogen, methyl, or ethyl;

R 10 represents from 1 to 5 substitutions for hydrogen, said substitutions independently chosen from:

i) fluoro;

ii) chloro;

iii) trifluoromethyl;

iv) methyl; or

v) two adjacent R 10 units can be taken together to form a 6-member ring having one or two oxygen atoms, provided no two oxygen atoms are adjacent to one another in the ring; and

pharmaceutically acceptable salts thereof; and

B) one or more pharmaceutically acceptable excipients.

31. The composition according to claim 30 , wherein the compound is {[5-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.

32. The compound {[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid.

Assignments (9)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 27445 FRAME: 100. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 17, 2024
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 067456/0592 →
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: THE PROCTER & GAMBLE COMPANY
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 059500/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: WU, SHENGDE; WARSHAKOON, NAMAL C.; EVDOKIMOV, ARTEM G.; GREIS, KENNETH D.; BOYER, ANGELIQUE SUN
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 059398/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: KAWAMOTO, RICHARD MASARU
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 059398/0372 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2011
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS INC.
Reel/Frame 027445/0100 →
PATENT RELEASE Recorded Dec 23, 2011
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 027443/0164 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →